Biomarkers in rheumatology, Now and in the future

David S. Gibson; Madeleine E. Rooney; Sorcha Finnegan; Ji Qiu; David C. Thompson; Joshua LaBaer; Stephen R. Pennington; Mark W. Duncan

doi:10.1093/rheumatology/ker358

Biomarkers in rheumatology, Now and in the future

David S. Gibson, Madeleine E. Rooney, Sorcha Finnegan, Ji Qiu, David C. Thompson, Joshua LaBaer, Stephen R. Pennington, Mark W. Duncan

Research output: Contribution to journal › Review article › peer-review

32 Scopus citations

Abstract

This review examines the biomarker development process by using rheumatic disorders as the disease model for discussion. We evaluate the current role of biomarkers in the practice of rheumatology and discuss their likely role in the future. We define the essential components of the biomarker development pipeline and discuss the issue of fitness for purpose, i.e. what the biomarker(s) might offer in a clinical setting. As a component of this review we also highlight several emerging technologies that are beginning to provide practical solutions to support biomarker validation. In the process, we highlight some scenarios where additional biomarkers would add considerable value to clinical practice, and we review appropriate methods for each. We also emphasize some important but infrequently discussed considerations, including the need for protein variant verification. Ultimately, the adroit application of the methods of proteomics will transform the practice rheumatology and allow personalized clinical practice to become a reality.

Original language	English (US)
Article number	ker358
Pages (from-to)	423-433
Number of pages	11
Journal	Rheumatology
Volume	51
Issue number	3
DOIs	https://doi.org/10.1093/rheumatology/ker358
State	Published - Mar 2012

Keywords

Arthritis
Biomarker validation
Mass spectrometry
Protein microarray
Proteomics
Targeted analysis
Validation
Verification

ASJC Scopus subject areas

Rheumatology
Pharmacology (medical)

Access to Document

10.1093/rheumatology/ker358

Cite this

@article{5f4ea93096fa41cc82661e92724e892a,

title = "Biomarkers in rheumatology, Now and in the future",

abstract = "This review examines the biomarker development process by using rheumatic disorders as the disease model for discussion. We evaluate the current role of biomarkers in the practice of rheumatology and discuss their likely role in the future. We define the essential components of the biomarker development pipeline and discuss the issue of fitness for purpose, i.e. what the biomarker(s) might offer in a clinical setting. As a component of this review we also highlight several emerging technologies that are beginning to provide practical solutions to support biomarker validation. In the process, we highlight some scenarios where additional biomarkers would add considerable value to clinical practice, and we review appropriate methods for each. We also emphasize some important but infrequently discussed considerations, including the need for protein variant verification. Ultimately, the adroit application of the methods of proteomics will transform the practice rheumatology and allow personalized clinical practice to become a reality.",

keywords = "Arthritis, Biomarker validation, Mass spectrometry, Protein microarray, Proteomics, Targeted analysis, Validation, Verification",

author = "Gibson, {David S.} and Rooney, {Madeleine E.} and Sorcha Finnegan and Ji Qiu and Thompson, {David C.} and Joshua LaBaer and Pennington, {Stephen R.} and Duncan, {Mark W.}",

note = "Funding Information: D.S.G. would like to acknowledge continued support from Arthritis Research UK in the form of a Travelling Fellowship (No. 19250). The UCD Conway Institute and the Proteome Research Centre are funded by the Programme for Research in Third Level Institutions, as administered by the Higher Education Authority of Ireland. SRP acknowledges support for equipment from Science Foundation Ireland. Funding Information: Biomarker research and grant funding",

year = "2012",

month = mar,

doi = "10.1093/rheumatology/ker358",

language = "English (US)",

volume = "51",

pages = "423--433",

journal = "Rheumatology",

issn = "1462-0324",

publisher = "Oxford University Press",

number = "3",

}

TY - JOUR

T1 - Biomarkers in rheumatology, Now and in the future

AU - Gibson, David S.

AU - Rooney, Madeleine E.

AU - Finnegan, Sorcha

AU - Qiu, Ji

AU - Thompson, David C.

AU - LaBaer, Joshua

AU - Pennington, Stephen R.

AU - Duncan, Mark W.

N1 - Funding Information: D.S.G. would like to acknowledge continued support from Arthritis Research UK in the form of a Travelling Fellowship (No. 19250). The UCD Conway Institute and the Proteome Research Centre are funded by the Programme for Research in Third Level Institutions, as administered by the Higher Education Authority of Ireland. SRP acknowledges support for equipment from Science Foundation Ireland. Funding Information: Biomarker research and grant funding

PY - 2012/3

Y1 - 2012/3

N2 - This review examines the biomarker development process by using rheumatic disorders as the disease model for discussion. We evaluate the current role of biomarkers in the practice of rheumatology and discuss their likely role in the future. We define the essential components of the biomarker development pipeline and discuss the issue of fitness for purpose, i.e. what the biomarker(s) might offer in a clinical setting. As a component of this review we also highlight several emerging technologies that are beginning to provide practical solutions to support biomarker validation. In the process, we highlight some scenarios where additional biomarkers would add considerable value to clinical practice, and we review appropriate methods for each. We also emphasize some important but infrequently discussed considerations, including the need for protein variant verification. Ultimately, the adroit application of the methods of proteomics will transform the practice rheumatology and allow personalized clinical practice to become a reality.

AB - This review examines the biomarker development process by using rheumatic disorders as the disease model for discussion. We evaluate the current role of biomarkers in the practice of rheumatology and discuss their likely role in the future. We define the essential components of the biomarker development pipeline and discuss the issue of fitness for purpose, i.e. what the biomarker(s) might offer in a clinical setting. As a component of this review we also highlight several emerging technologies that are beginning to provide practical solutions to support biomarker validation. In the process, we highlight some scenarios where additional biomarkers would add considerable value to clinical practice, and we review appropriate methods for each. We also emphasize some important but infrequently discussed considerations, including the need for protein variant verification. Ultimately, the adroit application of the methods of proteomics will transform the practice rheumatology and allow personalized clinical practice to become a reality.

KW - Arthritis

KW - Biomarker validation

KW - Mass spectrometry

KW - Protein microarray

KW - Proteomics

KW - Targeted analysis

KW - Validation

KW - Verification

UR - http://www.scopus.com/inward/record.url?scp=84857565407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857565407&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/ker358

DO - 10.1093/rheumatology/ker358

M3 - Review article

C2 - 22179724

AN - SCOPUS:84857565407

SN - 1462-0324

VL - 51

SP - 423

EP - 433

JO - Rheumatology

JF - Rheumatology

IS - 3

M1 - ker358

ER -

Biomarkers in rheumatology, Now and in the future

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this